![Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study - Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet ... Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study - Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet ...](https://journals.sagepub.com/cms/10.1177/1756284819878660/asset/images/large/10.1177_1756284819878660-fig2.jpeg)
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study - Nicolas Williet, Angélique Saint, Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet ...
![The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-32591-8/MediaObjects/41467_2022_32591_Fig1_HTML.png)
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma | Nature Communications
Potential biomarkers in nab-paclitaxel/gemcitabine (a), Folfirinox (b)... | Download Scientific Diagram
![Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer](https://pub.mdpi-res.com/life/life-12-00327/article_deploy/html/images/life-12-00327-ag.png?1645693413)
Life | Free Full-Text | A Review on the Efficacy and Safety of Nab- Paclitaxel with Gemcitabine in Combination with Other Therapeutic Agents as New Treatment Strategies in Pancreatic Cancer
![nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Semantic Scholar nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7332f742f7ef908ec7a925b5f894412ed89b4aac/3-Figure1-1.png)
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. | Semantic Scholar
![Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2059702920326375-gr1.jpg)
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer - ScienceDirect
![Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death](https://www.spandidos-publications.com/article_images/or/39/4/OR-39-04-1984-g03.jpg)
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
![Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine](https://www.thelancet.com/cms/attachment/84c1bf5a-f6d4-4102-a2d9-ae19220595ee/gr1.jpg)
Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial - eClinicalMedicine
![A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-023-11035-6/MediaObjects/12885_2023_11035_Fig1_HTML.png)
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01) | BMC Cancer | Full Text
![Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study](https://pub.mdpi-res.com/cancers/cancers-13-02797/article_deploy/html/images/cancers-13-02797-g001.png?1622795847)
Cancers | Free Full-Text | Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study
![Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan](https://journals.sagepub.com/cms/10.1177/17588359211035983/asset/images/large/10.1177_17588359211035983-fig1.jpeg)
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis - Jaekyung Cheon, Choong-kun Lee, Yun Beom Sang, Hye Jin Choi, Min Hwan
![A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921011655-ga1.jpg)
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact - ScienceDirect
![Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-5183-y/MediaObjects/12885_2018_5183_Fig1_HTML.png)
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group
![Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study | British Journal of Cancer Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-022-01713-w/MediaObjects/41416_2022_1713_Fig1_HTML.png)
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study | British Journal of Cancer
![Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921001064-gr1.jpg)
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial - ScienceDirect
![Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram](https://www.researchgate.net/publication/324194801/figure/fig2/AS:961421936451628@1606232260744/Subgroup-analyses-for-progression-free-survival-with-nab-paclitaxel-plus-gemcitabine-AG.gif)
Subgroup analyses for progression-free survival with nab-paclitaxel... | Download Scientific Diagram
![PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a8478459bead2b5ce4b12ab3728c7bfce9ce856a/4-Figure3-1.png)
PDF] Pomalidomide enhanced gemcitabine and nab-paclitaxel on pancreatic cancer both in vitro and in vivo | Semantic Scholar
![Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/e2916075-4a0f-4aac-8bbd-8817585876bd/gr1.gif)
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial - The Lancet Gastroenterology & Hepatology
![FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study](https://f6publishing.blob.core.windows.net/f27c62aa-018d-4bc2-9309-355b0fd824dd/WJGO-12-182-g001.png)
FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
![Nab-paclitaxel/gemcitabine combo boosts OS in resected pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Nab-paclitaxel/gemcitabine combo boosts OS in resected pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/F249F822-573B-41E0-9A85-AD9501412C9A/OriginalThumbnail/THUMBNAIL_shutterstock_1335637448.jpg)
Nab-paclitaxel/gemcitabine combo boosts OS in resected pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41420-023-01397-y/MediaObjects/41420_2023_1397_Fig1_HTML.png)